Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prazosin kinetics in hypertension

A Grahnén, P Seideman, B Lindström

    Clinical Pharmacology and Therapeutics
    |October 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Long-term Data from the Swedish National Environmental Monitoring Program of Pesticides in Surface Waters.

    Journal of environmental quality·2019
    Same author

    Future directions for the concept of salutogenesis: a position article.

    Health promotion international·2019
    Same author

    Auricular Acupuncture and Cognitive Behavioural Therapy for Insomnia: A Randomised Controlled Study.

    Sleep disorders·2016
    Same author

    Inorganic-carbon assimilation in the green seaweed Ulva rigida C.Ag. (Chlorophyta).

    Planta·2013
    Same author

    Role of carbonic anhydrase in photosynthesis and inorganic-carbon assimilation in the red alga Gracilaria tenuistipitata.

    Planta·2013
    Same author

    Role of external carbonic anhydrase in light-dependent alkalization by Fucus serratus L. and Laminaria saccharina (L.) Lamour. (Phaeophyta).

    Planta·2013

    Prazosin exhibits linear pharmacokinetics in hypertensive patients, with bioavailability varying due to absorption rather than liver metabolism. Plasma concentrations show significant inter-patient and intra-patient variability.

    Area of Science:

    • Pharmacology
    • Clinical Pharmacy

    Background:

    • Prazosin is an alpha-1 adrenergic blocker used to treat hypertension.
    • Understanding prazosin pharmacokinetics is crucial for optimizing therapeutic efficacy and minimizing adverse effects.

    Purpose of the Study:

    • To characterize the pharmacokinetic profile of prazosin after single and multiple doses in hypertensive patients.
    • To investigate the factors influencing prazosin bioavailability and plasma concentration variability.

    Main Methods:

    • Single intravenous and oral doses (0.5 mg) and multiple oral doses (0.5-5 mg TID) were administered to eight hypertensive patients.
    • Plasma samples were analyzed to determine prazosin concentrations over time.
    • Pharmacokinetic parameters including half-life, volume of distribution, clearance, and bioavailability were calculated.

    Related Experiment Videos

    Main Results:

    • Prazosin followed a linear two-compartment open model after IV administration, with a terminal half-life of approximately 3 hours and Vdβ of 0.6 L/kg.
    • Oral bioavailability ranged from 55% to 82%, with incomplete absorption identified as the primary cause of variability.
    • Total plasma clearance was low (0.14 L/kg·hr), and renal clearance was negligible.
    • Prazosin exhibited first-order kinetics with increasing multiple doses, demonstrating a linear relationship between dose and steady-state plasma concentration (P < 0.001).
    • Significant inter-patient and intra-patient variability in plasma concentrations was observed.

    Conclusions:

    • Prazosin absorption is incomplete, contributing to variable oral bioavailability.
    • The drug follows linear pharmacokinetics, but significant concentration variability necessitates careful patient monitoring.
    • Prazosin's pharmacokinetic profile suggests dose adjustments may be required to achieve therapeutic targets in hypertensive patients.